Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enteritis | 11 | 2024 | 19 | 5.760 |
Why?
|
| Gastritis | 11 | 2024 | 32 | 5.680 |
Why?
|
| Eosinophilia | 10 | 2024 | 37 | 4.780 |
Why?
|
| Eosinophilic Esophagitis | 12 | 2024 | 35 | 4.280 |
Why?
|
| Eosinophils | 5 | 2024 | 39 | 2.190 |
Why?
|
| Desensitization, Immunologic | 6 | 2022 | 108 | 1.910 |
Why?
|
| Colitis | 2 | 2019 | 51 | 1.300 |
Why?
|
| Allergens | 4 | 2024 | 140 | 0.910 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2022 | 73 | 0.770 |
Why?
|
| Hypersensitivity | 2 | 2023 | 77 | 0.760 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 121 | 0.750 |
Why?
|
| Anaphylaxis | 2 | 2018 | 71 | 0.720 |
Why?
|
| Gastroenteritis | 1 | 2019 | 17 | 0.670 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 33 | 0.660 |
Why?
|
| Esophagus | 3 | 2024 | 84 | 0.650 |
Why?
|
| Acetazolamide | 1 | 2018 | 18 | 0.630 |
Why?
|
| Pseudotumor Cerebri | 1 | 2018 | 24 | 0.620 |
Why?
|
| Drug Hypersensitivity | 1 | 2018 | 36 | 0.610 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 215 | 0.610 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 160 | 0.600 |
Why?
|
| Drug Design | 1 | 2018 | 121 | 0.590 |
Why?
|
| Anticonvulsants | 1 | 2018 | 122 | 0.580 |
Why?
|
| Immunoglobulin E | 2 | 2016 | 92 | 0.560 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 449 | 0.550 |
Why?
|
| Food Hypersensitivity | 2 | 2017 | 101 | 0.520 |
Why?
|
| Immune Tolerance | 4 | 2022 | 95 | 0.520 |
Why?
|
| Child | 16 | 2024 | 6851 | 0.500 |
Why?
|
| Humans | 30 | 2024 | 50208 | 0.500 |
Why?
|
| Schnitzler Syndrome | 1 | 2014 | 4 | 0.490 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 75 | 0.460 |
Why?
|
| Child, Preschool | 10 | 2024 | 3883 | 0.450 |
Why?
|
| Peanut Hypersensitivity | 3 | 2022 | 88 | 0.450 |
Why?
|
| Mycobacterium fortuitum | 1 | 2013 | 6 | 0.440 |
Why?
|
| Macrolides | 1 | 2013 | 16 | 0.440 |
Why?
|
| Clarithromycin | 1 | 2013 | 38 | 0.430 |
Why?
|
| Milk Hypersensitivity | 2 | 2024 | 19 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 460 | 0.360 |
Why?
|
| Urticaria | 3 | 2015 | 18 | 0.360 |
Why?
|
| Infant | 8 | 2024 | 3563 | 0.350 |
Why?
|
| Adolescent | 7 | 2024 | 6390 | 0.350 |
Why?
|
| Proton Pump Inhibitors | 3 | 2024 | 85 | 0.340 |
Why?
|
| Asthma | 2 | 2023 | 280 | 0.340 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 466 | 0.320 |
Why?
|
| Female | 16 | 2024 | 26635 | 0.320 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2024 | 225 | 0.310 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5155 | 0.300 |
Why?
|
| Synbiotics | 2 | 2024 | 3 | 0.280 |
Why?
|
| Administration, Oral | 3 | 2022 | 434 | 0.270 |
Why?
|
| Male | 14 | 2024 | 25399 | 0.260 |
Why?
|
| Allergy and Immunology | 1 | 2024 | 14 | 0.240 |
Why?
|
| Congresses as Topic | 1 | 2024 | 43 | 0.240 |
Why?
|
| Infant Formula | 2 | 2024 | 143 | 0.220 |
Why?
|
| United States | 3 | 2024 | 4874 | 0.220 |
Why?
|
| Amino Acids | 2 | 2024 | 362 | 0.210 |
Why?
|
| Food Supply | 1 | 2023 | 91 | 0.210 |
Why?
|
| Outpatients | 1 | 2023 | 112 | 0.210 |
Why?
|
| Middle Aged | 6 | 2021 | 12206 | 0.200 |
Why?
|
| Parents | 1 | 2024 | 315 | 0.190 |
Why?
|
| Adult | 7 | 2023 | 13324 | 0.190 |
Why?
|
| Young Adult | 3 | 2019 | 3981 | 0.190 |
Why?
|
| Quality of Life | 2 | 2024 | 839 | 0.190 |
Why?
|
| Injections, Subcutaneous | 2 | 2024 | 54 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 2190 | 0.180 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 695 | 0.170 |
Why?
|
| Biological Therapy | 1 | 2019 | 16 | 0.170 |
Why?
|
| Standard of Care | 1 | 2019 | 16 | 0.170 |
Why?
|
| Leukocyte Count | 1 | 2019 | 72 | 0.170 |
Why?
|
| Ulcer | 1 | 2019 | 22 | 0.170 |
Why?
|
| Erythema | 1 | 2019 | 38 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 89 | 0.170 |
Why?
|
| Double-Blind Method | 4 | 2024 | 688 | 0.170 |
Why?
|
| Colon | 1 | 2019 | 94 | 0.170 |
Why?
|
| Intestine, Small | 1 | 2019 | 108 | 0.160 |
Why?
|
| Stomach | 1 | 2019 | 79 | 0.160 |
Why?
|
| Retrospective Studies | 3 | 2019 | 6134 | 0.160 |
Why?
|
| Epinephrine | 2 | 2016 | 96 | 0.160 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2018 | 11 | 0.160 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2018 | 2 | 0.160 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2018 | 3 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 150 | 0.160 |
Why?
|
| Disease Management | 1 | 2019 | 176 | 0.150 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 636 | 0.150 |
Why?
|
| Biopsy | 1 | 2019 | 590 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2017 | 49 | 0.140 |
Why?
|
| Inflammation | 1 | 2021 | 604 | 0.140 |
Why?
|
| Particulate Matter | 1 | 2017 | 52 | 0.140 |
Why?
|
| Immunization | 1 | 2017 | 67 | 0.140 |
Why?
|
| Comorbidity | 1 | 2019 | 613 | 0.140 |
Why?
|
| Seasons | 1 | 2017 | 82 | 0.140 |
Why?
|
| Consensus | 3 | 2022 | 150 | 0.140 |
Why?
|
| Deglutition Disorders | 1 | 2017 | 77 | 0.140 |
Why?
|
| Sympathomimetics | 1 | 2016 | 21 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2018 | 226 | 0.130 |
Why?
|
| Incidence | 1 | 2019 | 1006 | 0.130 |
Why?
|
| Disaccharides | 1 | 2015 | 10 | 0.130 |
Why?
|
| Environmental Exposure | 1 | 2017 | 199 | 0.130 |
Why?
|
| Meat | 1 | 2015 | 61 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2019 | 1422 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2018 | 476 | 0.130 |
Why?
|
| Prospective Studies | 2 | 2021 | 2379 | 0.130 |
Why?
|
| Celiac Disease | 1 | 2014 | 9 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2014 | 54 | 0.110 |
Why?
|
| Animals | 3 | 2024 | 13246 | 0.110 |
Why?
|
| Fever | 1 | 2014 | 115 | 0.110 |
Why?
|
| Amikacin | 1 | 2013 | 19 | 0.110 |
Why?
|
| Azithromycin | 1 | 2013 | 25 | 0.110 |
Why?
|
| Skin Tests | 1 | 2013 | 58 | 0.110 |
Why?
|
| Arkansas | 1 | 2017 | 1985 | 0.100 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1043 | 0.090 |
Why?
|
| Aged | 2 | 2021 | 9405 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 951 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 486 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2021 | 2766 | 0.070 |
Why?
|
| Interleukin-13 | 1 | 2024 | 15 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2024 | 43 | 0.060 |
Why?
|
| Remission Induction | 1 | 2024 | 207 | 0.060 |
Why?
|
| Cattle | 1 | 2024 | 219 | 0.060 |
Why?
|
| Milk | 1 | 2024 | 79 | 0.060 |
Why?
|
| Spirometry | 1 | 2023 | 29 | 0.050 |
Why?
|
| Self Report | 1 | 2024 | 199 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2023 | 137 | 0.050 |
Why?
|
| International Cooperation | 1 | 2021 | 44 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2023 | 213 | 0.050 |
Why?
|
| Health Promotion | 1 | 2023 | 267 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1378 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2023 | 360 | 0.040 |
Why?
|
| Constipation | 1 | 2017 | 35 | 0.040 |
Why?
|
| Vomiting | 1 | 2017 | 75 | 0.040 |
Why?
|
| Diarrhea | 1 | 2017 | 92 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 2016 | 19 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 53 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 863 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 346 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 230 | 0.030 |
Why?
|
| Swine | 1 | 2015 | 396 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 550 | 0.030 |
Why?
|